Sheng-Rong Meng, Chao Ma, Jie Chen, Li-Qiang Wang, Hong-Yu Hu, Yi Liang
{"title":"通过扫描脯氨酸诱变揭示非扩展共济失调蛋白-3的纤维形成基序","authors":"Sheng-Rong Meng, Chao Ma, Jie Chen, Li-Qiang Wang, Hong-Yu Hu, Yi Liang","doi":"10.20517/and.2023.15","DOIUrl":null,"url":null,"abstract":"Aims: The misfolding of ataxin-3 in neurons is the hallmark of a neurodegenerative disease, spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD). Ataxin-3 consists of a N-terminal Josephin domain and a C-terminal polyglutamine (polyQ) tract. The length of the polyQ tract is positively correlated with the disease. The aggregation of ataxin-3 in vitro is a two-step process, with the first step involving the aggregation of the Josephin domain and the second step involving an expanded polyQ tract. However, the fibril-forming motif of the Josephin domain is not well understood.\n Methods: In this study, we employed 3D profile algorithm and scanning proline mutagenesis to identify the fibril-forming motif of non-expanded ataxin-3.\n Results: By using thioflavin T fluorescence kinetics, sarkosyl-insoluble SDS-PAGE, transmission electron microscopy (TEM), and Fourier transform infrared spectroscopy (FTIR), we identified the fibril-forming motif of the Josephin domain of non-expanded ataxin-3 as 79VISNAL84.\n Conclusions: We demonstrated that the proline mutation in the fibril-forming motif of the Josephin domain could inhibit the aggregation of expanded ataxin-3, which shows some therapeutic promise.","PeriodicalId":93251,"journal":{"name":"Ageing and neurodegenerative diseases","volume":"50 17","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fibril-forming motif of non-expanded ataxin-3 revealed by scanning proline mutagenesis\",\"authors\":\"Sheng-Rong Meng, Chao Ma, Jie Chen, Li-Qiang Wang, Hong-Yu Hu, Yi Liang\",\"doi\":\"10.20517/and.2023.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aims: The misfolding of ataxin-3 in neurons is the hallmark of a neurodegenerative disease, spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD). Ataxin-3 consists of a N-terminal Josephin domain and a C-terminal polyglutamine (polyQ) tract. The length of the polyQ tract is positively correlated with the disease. The aggregation of ataxin-3 in vitro is a two-step process, with the first step involving the aggregation of the Josephin domain and the second step involving an expanded polyQ tract. However, the fibril-forming motif of the Josephin domain is not well understood.\\n Methods: In this study, we employed 3D profile algorithm and scanning proline mutagenesis to identify the fibril-forming motif of non-expanded ataxin-3.\\n Results: By using thioflavin T fluorescence kinetics, sarkosyl-insoluble SDS-PAGE, transmission electron microscopy (TEM), and Fourier transform infrared spectroscopy (FTIR), we identified the fibril-forming motif of the Josephin domain of non-expanded ataxin-3 as 79VISNAL84.\\n Conclusions: We demonstrated that the proline mutation in the fibril-forming motif of the Josephin domain could inhibit the aggregation of expanded ataxin-3, which shows some therapeutic promise.\",\"PeriodicalId\":93251,\"journal\":{\"name\":\"Ageing and neurodegenerative diseases\",\"volume\":\"50 17\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ageing and neurodegenerative diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20517/and.2023.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing and neurodegenerative diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20517/and.2023.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:神经元中的共济失调蛋白-3(ataxin-3)的错误折叠是一种神经退行性疾病--脊髓小脑共济失调 3 型(SCA3)(又称马查多-约瑟夫病(MJD))的特征。Ataxin-3 由一个 N 端约瑟芬结构域和一个 C 端聚谷氨酰胺(polyQ)束组成。聚Q束的长度与疾病呈正相关。Ataxin-3 在体外的聚集过程分为两步,第一步涉及 Josephin 结构域的聚集,第二步涉及 polyQ 道的扩展。然而,Josephin 结构域的纤维形成基序尚不十分清楚。研究方法在这项研究中,我们采用了三维剖面算法和扫描脯氨酸诱变来确定非扩展的 ataxin-3 的纤维形成基调。结果通过使用硫黄素 T 荧光动力学、Sarkosyl-不溶性 SDS-PAGE、透射电子显微镜(TEM)和傅立叶变换红外光谱(FTIR),我们确定了非扩张型 ataxin-3 的 Josephin 结构域的纤维形成基序为 79VISNAL84。结论:我们证明了约瑟芬结构域纤维形成基团中的脯氨酸突变可抑制扩增的共济失调蛋白-3的聚集,具有一定的治疗前景。
Fibril-forming motif of non-expanded ataxin-3 revealed by scanning proline mutagenesis
Aims: The misfolding of ataxin-3 in neurons is the hallmark of a neurodegenerative disease, spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD). Ataxin-3 consists of a N-terminal Josephin domain and a C-terminal polyglutamine (polyQ) tract. The length of the polyQ tract is positively correlated with the disease. The aggregation of ataxin-3 in vitro is a two-step process, with the first step involving the aggregation of the Josephin domain and the second step involving an expanded polyQ tract. However, the fibril-forming motif of the Josephin domain is not well understood.
Methods: In this study, we employed 3D profile algorithm and scanning proline mutagenesis to identify the fibril-forming motif of non-expanded ataxin-3.
Results: By using thioflavin T fluorescence kinetics, sarkosyl-insoluble SDS-PAGE, transmission electron microscopy (TEM), and Fourier transform infrared spectroscopy (FTIR), we identified the fibril-forming motif of the Josephin domain of non-expanded ataxin-3 as 79VISNAL84.
Conclusions: We demonstrated that the proline mutation in the fibril-forming motif of the Josephin domain could inhibit the aggregation of expanded ataxin-3, which shows some therapeutic promise.